EA200200510A1 - 4-CARBOXYAMINO-2-ETHYL-1,2,3,4-TETRAHYDROCHINOLINE IN A CRYSTAL FORM AS A CETR INHIBITOR - Google Patents
4-CARBOXYAMINO-2-ETHYL-1,2,3,4-TETRAHYDROCHINOLINE IN A CRYSTAL FORM AS A CETR INHIBITORInfo
- Publication number
- EA200200510A1 EA200200510A1 EA200200510A EA200200510A EA200200510A1 EA 200200510 A1 EA200200510 A1 EA 200200510A1 EA 200200510 A EA200200510 A EA 200200510A EA 200200510 A EA200200510 A EA 200200510A EA 200200510 A1 EA200200510 A1 EA 200200510A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inhibitor
- tetrahydrochinoline
- cetr
- carboxyamino
- ethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Описываются кристаллические формы ингибитора СЕТР формулы (I), способы получения кристаллических форм, способы применения кристаллических форм и фармацевтические композиции, содержащие кристаллические формы.Международная заявка была опубликована вместе с отчетом о международном поиске.The crystal forms of the CETP inhibitor of formula (I), methods for producing crystalline forms, methods for using crystalline forms and pharmaceutical compositions containing crystalline forms are described. The international application was published together with an international search report.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16805199P | 1999-11-30 | 1999-11-30 | |
PCT/IB2000/001650 WO2001040190A1 (en) | 1999-11-30 | 2000-11-14 | 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200200510A1 true EA200200510A1 (en) | 2002-10-31 |
Family
ID=22609901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200200510A EA200200510A1 (en) | 1999-11-30 | 2000-11-14 | 4-CARBOXYAMINO-2-ETHYL-1,2,3,4-TETRAHYDROCHINOLINE IN A CRYSTAL FORM AS A CETR INHIBITOR |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1246804A1 (en) |
JP (1) | JP2003515592A (en) |
KR (1) | KR20020058057A (en) |
CN (1) | CN1402711A (en) |
AP (1) | AP2002002531A0 (en) |
AU (1) | AU1048801A (en) |
BG (1) | BG106854A (en) |
BR (1) | BR0015836A (en) |
CA (1) | CA2392979A1 (en) |
CO (1) | CO5271716A1 (en) |
EA (1) | EA200200510A1 (en) |
EC (1) | ECSP003792A (en) |
EE (1) | EE200200277A (en) |
GT (1) | GT200000199A (en) |
HU (1) | HUP0203521A2 (en) |
IL (1) | IL149097A0 (en) |
IS (1) | IS6338A (en) |
MA (1) | MA26845A1 (en) |
MX (1) | MXPA02005354A (en) |
NO (1) | NO20022558L (en) |
OA (1) | OA12099A (en) |
PA (1) | PA8506301A1 (en) |
PE (1) | PE20010904A1 (en) |
PL (1) | PL355892A1 (en) |
TN (1) | TNSN00231A1 (en) |
TR (1) | TR200201446T2 (en) |
UY (1) | UY26454A1 (en) |
WO (1) | WO2001040190A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
HUP0400263A2 (en) | 2001-06-21 | 2005-03-29 | Pfizer Products Inc. | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
GT200200170A (en) * | 2001-09-28 | 2003-05-23 | PREPARATION OF INHIBITOR OF CETP ANHIDRO | |
KR100664822B1 (en) * | 2002-02-01 | 2007-01-04 | 화이자 프로덕츠 인코포레이티드 | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
CA2474838C (en) | 2002-02-01 | 2009-01-06 | Pfizer Products Inc. | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
EP1920766B1 (en) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
ES2277142T3 (en) | 2002-08-30 | 2007-07-01 | Japan Tobacco Inc. | DIBENCILAMINE COMPOSITE AND ITS MEDICINAL USE. |
EP1556047A4 (en) | 2002-10-04 | 2009-09-30 | Millennium Pharm Inc | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
WO2004056358A1 (en) | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
CN1795177A (en) * | 2003-03-28 | 2006-06-28 | 辉瑞产品公司 | 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity |
WO2005011635A2 (en) | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
ATE442358T1 (en) | 2003-10-08 | 2009-09-15 | Lilly Co Eli | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA |
AU2005233160B2 (en) * | 2004-04-13 | 2011-06-02 | Merck Sharp & Dohme Corp. | CETP inhibitors |
JP2008504266A (en) * | 2004-06-24 | 2008-02-14 | イーライ リリー アンド カンパニー | Compounds and methods for treating dyslipidemia |
WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
US20070149567A1 (en) * | 2004-09-23 | 2007-06-28 | Pfizer Inc | Quinoline compounds |
BRPI0608553A2 (en) | 2005-02-24 | 2010-01-12 | Millennium Pharm Inc | pgd2 receptor antagonists for the treatment of inflammatory diseases |
WO2006098394A1 (en) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | Method for inhibiting lipid absorption and lipid absorption inhibitor |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
AR065670A1 (en) | 2007-03-09 | 2009-06-24 | Indigene Pharmaceuticals Inc | COMBINATION OF METFORMIN R - (+) LIPOATE AND ANTIHIPERLIPIDEMIC AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLUCEMIA AND DIABETIC COMPLICATIONS |
US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
TWI450896B (en) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid |
MX2017000582A (en) | 2014-07-30 | 2017-04-27 | Hoffmann La Roche | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent. |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
WO1998033775A1 (en) * | 1997-02-03 | 1998-08-06 | American Home Products Corporation | 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
-
2000
- 2000-11-09 CO CO00085285A patent/CO5271716A1/en unknown
- 2000-11-13 PA PA20008506301A patent/PA8506301A1/en unknown
- 2000-11-14 KR KR1020027006914A patent/KR20020058057A/en not_active Application Discontinuation
- 2000-11-14 WO PCT/IB2000/001650 patent/WO2001040190A1/en not_active Application Discontinuation
- 2000-11-14 IL IL14909700A patent/IL149097A0/en unknown
- 2000-11-14 AP APAP/P/2002/002531A patent/AP2002002531A0/en unknown
- 2000-11-14 JP JP2001541875A patent/JP2003515592A/en active Pending
- 2000-11-14 OA OA1200200158A patent/OA12099A/en unknown
- 2000-11-14 PL PL00355892A patent/PL355892A1/en not_active Application Discontinuation
- 2000-11-14 EP EP00971662A patent/EP1246804A1/en not_active Withdrawn
- 2000-11-14 BR BR0015836-4A patent/BR0015836A/en not_active IP Right Cessation
- 2000-11-14 AU AU10488/01A patent/AU1048801A/en not_active Abandoned
- 2000-11-14 TR TR2002/01446T patent/TR200201446T2/en unknown
- 2000-11-14 HU HU0203521A patent/HUP0203521A2/en unknown
- 2000-11-14 CA CA002392979A patent/CA2392979A1/en not_active Abandoned
- 2000-11-14 EA EA200200510A patent/EA200200510A1/en unknown
- 2000-11-14 MX MXPA02005354A patent/MXPA02005354A/en unknown
- 2000-11-14 EE EEP200200277A patent/EE200200277A/en unknown
- 2000-11-14 CN CN00816463A patent/CN1402711A/en active Pending
- 2000-11-28 UY UY26454A patent/UY26454A1/en not_active Application Discontinuation
- 2000-11-28 PE PE2000001267A patent/PE20010904A1/en not_active Application Discontinuation
- 2000-11-29 TN TNTNSN00231A patent/TNSN00231A1/en unknown
- 2000-11-29 EC EC2000003792A patent/ECSP003792A/en unknown
- 2000-11-29 GT GT200000199A patent/GT200000199A/en unknown
-
2002
- 2002-04-12 IS IS6338A patent/IS6338A/en unknown
- 2002-05-27 MA MA26653A patent/MA26845A1/en unknown
- 2002-05-29 NO NO20022558A patent/NO20022558L/en not_active Application Discontinuation
- 2002-06-20 BG BG106854A patent/BG106854A/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO20022558D0 (en) | 2002-05-29 |
KR20020058057A (en) | 2002-07-12 |
PE20010904A1 (en) | 2001-09-10 |
HUP0203521A2 (en) | 2003-02-28 |
PL355892A1 (en) | 2004-05-31 |
ECSP003792A (en) | 2002-04-23 |
CO5271716A1 (en) | 2003-04-30 |
IS6338A (en) | 2002-04-12 |
JP2003515592A (en) | 2003-05-07 |
EP1246804A1 (en) | 2002-10-09 |
EE200200277A (en) | 2003-10-15 |
IL149097A0 (en) | 2002-11-10 |
AP2002002531A0 (en) | 2002-06-30 |
CA2392979A1 (en) | 2001-06-07 |
MXPA02005354A (en) | 2002-12-11 |
MA26845A1 (en) | 2004-12-20 |
PA8506301A1 (en) | 2002-08-26 |
TNSN00231A1 (en) | 2002-05-30 |
UY26454A1 (en) | 2001-07-31 |
TR200201446T2 (en) | 2002-11-21 |
CN1402711A (en) | 2003-03-12 |
GT200000199A (en) | 2002-05-23 |
AU1048801A (en) | 2001-06-12 |
NO20022558L (en) | 2002-05-29 |
OA12099A (en) | 2006-05-04 |
BR0015836A (en) | 2002-08-06 |
WO2001040190A1 (en) | 2001-06-07 |
BG106854A (en) | 2002-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200200510A1 (en) | 4-CARBOXYAMINO-2-ETHYL-1,2,3,4-TETRAHYDROCHINOLINE IN A CRYSTAL FORM AS A CETR INHIBITOR | |
DE69413542D1 (en) | PERHYDROISOINDOL DERIVATIVES AS SUBSTANCE P ANTAGONISTS | |
EA200500017A1 (en) | NEW CONNECTIONS | |
DE69325454T2 (en) | TAXOL DERIVATIVES | |
DK0931788T3 (en) | metalloprotease | |
BG103485A (en) | Ketobanzamides as calpain inhibitors | |
NO20025590D0 (en) | Phenylglycine derivatives | |
ES2136037A1 (en) | Sulfamide-metalloprotease inhibitors | |
EA200000826A1 (en) | HALIDATED DERIVATIVES OF AMIDINOMOMINO ACIDS APPLICABLE AS NO-SYNTHASE INHIBITORS | |
FI934298A0 (en) | CRYSTAL TIAGABINE HYDROCHLORIDE MONOHYDRATE, DESS FRAMSTAELLNING OCH DESS ANVAENDNING | |
DE50209545D1 (en) | LIQUID CRYSTALLINE MEDIUM | |
FI955498A0 (en) | Nipecotinic acid derivatives as anticoagulants | |
SE9903290D0 (en) | Novel compounds | |
MXPA04009421A (en) | Thiazol-2-yl-imine compounds as pde-7 inhibitors. | |
BR9713176A (en) | Amorphous benzothiophenes, methods of preparation and methods of use | |
DE69330601D1 (en) | SEROTON INERGIC ERGOLIN DERIVATIVES | |
FI963168A0 (en) | New Indan-2-Mercaptoacetylamide Disulfide Derivatives Useful as Enkephalinase Inhibitors | |
ES2128031T3 (en) | CRYSTALLINE AND POLYMORPHIC FORM OF (S, S, S) -N- (1- (2-CARBOXI-3- (N2-MESILISILAMINO) PROPIL) -1-CYCLOPENYL CARBONYL) THYROSINE. | |
DE59803066D1 (en) | SUBSTITUTED BENZYLOXYIMINO COMPOUNDS | |
TR200001122T2 (en) | Biphenyl derivatives as pharmaceuticals. | |
FI960588A (en) | Thiocarbamoyl compounds useful as microbicides | |
NO20053117L (en) | Cyclopenta [c] isoxazole-3-amines used as material protecting agents. | |
SU1690339A1 (en) | N- (3-CHLORO-1,4-NAFTOKHINONIL-2) -2-D, L-ASPARAGIC ACID, DISPLAYING CARDIOSTIMULATING PROPERTIES | |
AP2001002047A0 (en) | Isoquinoliness as urokinase inhibitors. |